SC379 / Sana Biotech - LARVOL DELTA

Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions (GlobeNewswire) - "Sana Biotechnology, Inc...today highlighted that Nature Biotechnology has published a paper...This paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) – the cells that give rise to the glial support cells of the brain – were transplanted into adult mice that had been neonatally transplanted with mutant Huntingtin (mHTT)-expressing hGPCs, the healthy cells outcompeted and eliminated the diseased glia, ultimately repopulating the brain with the healthy transplanted cells. These data establish an additional proof-of-concept for the development of SC379...'Our goal is to begin clinical testing of SC379 as early as 2025.'"

New trial • Preclinical • CNS Disorders • Huntington's Disease • Multiple Sclerosis